Ensysce Biosciences (NASDAQ:ENSC) Announces Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Ensysce Biosciences (NASDAQ:ENSC) posted its quarterly earnings results on Monday. The company reported ($2.90) earnings per share for the quarter, missing the consensus estimate of ($2.74) by ($0.16), Zacks reports. Ensysce Biosciences had a negative net margin of 179.26% and a negative return on equity of 292.81%.

Ensysce Biosciences Stock Performance

Ensysce Biosciences stock traded down $0.19 during mid-day trading on Monday, reaching $4.83. The stock had a trading volume of 15,631 shares, compared to its average volume of 507,712. Ensysce Biosciences has a fifty-two week low of $2.12 and a fifty-two week high of $14.67. The firm has a market capitalization of $6.31 million, a PE ratio of -0.18 and a beta of 0.64. The stock’s 50-day simple moving average is $6.68 and its 200-day simple moving average is $6.55.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.